Application of Guideline Recommended Treatment in Routine Clinical Practice: A Population-based Study of Stage I-IIIB Non-small Cell Lung Cancer

被引:18
作者
Duggan, K. J. [1 ]
Descallar, J. [2 ,3 ]
Vinod, S. K. [3 ,4 ,5 ]
机构
[1] Liverpool Hosp, South West Sydney & Sydney Local Hlth Dist Clin C, Sydney, NSW, Australia
[2] Liverpool Hosp, Ingham Inst Appl Med Res, Sydney, NSW, Australia
[3] Univ New South Wales, South West Sydney Clin Sch, Sydney, NSW, Australia
[4] Liverpool Hosp, Canc Therapy Ctr, Sydney, NSW, Australia
[5] Univ Western Sydney, Sydney, NSW, Australia
关键词
Cancer registry; carcinoma; guideline adherence; lung neoplasms; non-small cell lung; treatment utilisation; ELDERLY-PATIENTS; CARE; SURVIVAL; AGE; CHEMOTHERAPY; COMORBIDITY; DISPARITIES; PATTERNS; TRIALS; IMPACT;
D O I
10.1016/j.clon.2016.04.045
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Aims: The application of guideline recommended treatment (GRT) in routine clinical practice can be difficult due to differences between the clinic population and the clinical trial populations on which evidence is based. The study aims were to measure receipt of GRT in stage I-IIIB non-small cell lung cancer (NSCLC) patients, identify factors associated with GRT and its impact on survival. Materials and methods: New diagnoses of stage I-IIIB NSCLC from 1 January 2006 to 31 December 2011 in South West Sydney residents were identified from the district Clinical Cancer Registry. Treatment received was assigned as GRT or not based on Australian guidelines (using Eastern Cooperative Oncology Group [ECOG] performance status and TNM stage). Multivariate Poisson regression models with robust variance identified predictors of GRT receipt. Cox regression models identified multivariate predictors of patient survival. Results: In total, 592 eligible cases were identified, of whom 66% (n = 389) received GRT. This ranged from 81% of stage I to 39% of stage I-IIIB (relative risk 0.48, 0.38-0.60, P < 0.0001). Stage I-IIIA patients who were ECOG 2 and stage III patients aged 70 years and older were less likely to receive GRT. The median survival was 30 months in the GRT group and 16 months in the non-GRT group (P < 0.001). GRT receipt was associated with improved survival in stage I-II disease only (hazard ratio 0.41, P < 0.001; and hazard ratio 0.43, P = 0.006). Conclusion: One-third of NSCLC patients did not receive GRT. Stage and performance status were key predictors for GRT receipt. Patients with early stage NSCLC were associated with improved survival with the receipt of GRT. (C) 2016 The Royal College of Radiologists. Published by Elsevier Ltd. All rights reserved.
引用
收藏
页码:639 / 647
页数:9
相关论文
共 23 条
[1]  
Australian Bureau of Statistics, 2008, INF PAP INTR SOC IND
[2]  
Australian Cancer Council, 2004, CLIN PRACT GUID PREV
[3]   Alternatives for logistic regression in cross-sectional studies: An empirical comparison of models that directly estimate the prevalence ratio [J].
Aluísio JD Barros ;
Vânia N Hirakata .
BMC Medical Research Methodology, 3 (1) :1-13
[4]   Do Multidisciplinary Team Meetings Make a Difference in the Management of Lung Cancer? [J].
Boxer, Miriam M. ;
Vinod, Shalini K. ;
Shafiq, Jesmin ;
Duggan, Kirsten J. .
CANCER, 2011, 117 (22) :5112-5120
[5]   The impact of case discussion at a multidisciplinary team meeting on the treatment and survival of patients with inoperable non-small cell lung cancer [J].
Bydder, S. ;
Nowak, A. ;
Marion, K. ;
Phillips, M. ;
Atun, R. .
INTERNAL MEDICINE JOURNAL, 2009, 39 (12) :838-841
[6]   Influence of age, comorbidity and performance status on the choice of treatment for patients with non-small cell lung cancer; results of a population-based study [J].
de Rijke, JM ;
Schouten, LJ ;
ten Velde, GPM ;
Wanders, SL ;
Bollen, ECM ;
Lalisang, RI ;
van Dijck, JAAM ;
Kramer, GWP ;
van den Brandt, PA .
LUNG CANCER, 2004, 46 (02) :233-245
[7]  
Edge S.B., 2010, AJCC Cancer Staging Manual, V7th, P649
[8]   Increasing underrepresentation of elderly patients with advanced colorectal or non-small-cell lung cancer in chemotherapy trials [J].
Jennens, RR ;
Giles, GG ;
Fox, RM .
INTERNAL MEDICINE JOURNAL, 2006, 36 (04) :216-220
[9]   Patterns of care survey (PCS) in lung cancer: how well does current US practice with chemotherapy in the non-metastatic setting follow the literature? [J].
Langer, CJ ;
Moughan, J ;
Movsas, B ;
Komaki, R ;
Ettinger, D ;
Owen, J ;
Wilson, JF .
LUNG CANCER, 2005, 48 (01) :93-102
[10]   Participation in cancer clinical trials - Race-, sex-, and age-based disparities [J].
Murthy, VH ;
Krumholz, HM ;
Gross, CP .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2004, 291 (22) :2720-2726